|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TAOK2 |
Gene summary for TAOK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TAOK2 | Gene ID | 9344 |
| Gene name | TAO kinase 2 | |
| Gene Alias | MAP3K17 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q9UL54 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9344 | TAOK2 | LZE24T | Human | Esophagus | ESCC | 1.43e-15 | 4.44e-01 | 0.0596 |
| 9344 | TAOK2 | LZE21T | Human | Esophagus | ESCC | 4.45e-03 | 2.48e-01 | 0.0655 |
| 9344 | TAOK2 | P1T-E | Human | Esophagus | ESCC | 3.00e-02 | 2.66e-01 | 0.0875 |
| 9344 | TAOK2 | P2T-E | Human | Esophagus | ESCC | 5.26e-13 | 1.90e-01 | 0.1177 |
| 9344 | TAOK2 | P4T-E | Human | Esophagus | ESCC | 2.01e-07 | 1.27e-01 | 0.1323 |
| 9344 | TAOK2 | P8T-E | Human | Esophagus | ESCC | 8.63e-08 | 1.82e-01 | 0.0889 |
| 9344 | TAOK2 | P10T-E | Human | Esophagus | ESCC | 1.15e-04 | 1.03e-01 | 0.116 |
| 9344 | TAOK2 | P11T-E | Human | Esophagus | ESCC | 1.02e-05 | 2.22e-01 | 0.1426 |
| 9344 | TAOK2 | P12T-E | Human | Esophagus | ESCC | 6.82e-12 | 2.08e-01 | 0.1122 |
| 9344 | TAOK2 | P15T-E | Human | Esophagus | ESCC | 2.68e-07 | 1.63e-01 | 0.1149 |
| 9344 | TAOK2 | P16T-E | Human | Esophagus | ESCC | 4.35e-08 | 7.35e-02 | 0.1153 |
| 9344 | TAOK2 | P17T-E | Human | Esophagus | ESCC | 2.95e-07 | 2.09e-01 | 0.1278 |
| 9344 | TAOK2 | P20T-E | Human | Esophagus | ESCC | 4.32e-12 | 1.85e-01 | 0.1124 |
| 9344 | TAOK2 | P21T-E | Human | Esophagus | ESCC | 4.47e-06 | 1.56e-01 | 0.1617 |
| 9344 | TAOK2 | P22T-E | Human | Esophagus | ESCC | 7.03e-07 | 9.03e-02 | 0.1236 |
| 9344 | TAOK2 | P23T-E | Human | Esophagus | ESCC | 1.81e-06 | 1.56e-01 | 0.108 |
| 9344 | TAOK2 | P24T-E | Human | Esophagus | ESCC | 3.22e-06 | 1.30e-01 | 0.1287 |
| 9344 | TAOK2 | P26T-E | Human | Esophagus | ESCC | 1.21e-04 | 9.99e-02 | 0.1276 |
| 9344 | TAOK2 | P27T-E | Human | Esophagus | ESCC | 2.84e-10 | 1.37e-01 | 0.1055 |
| 9344 | TAOK2 | P28T-E | Human | Esophagus | ESCC | 4.28e-12 | 2.27e-01 | 0.1149 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:19019905 | Oral cavity | OSCC | regulation of mitotic cell cycle phase transition | 173/7305 | 299/18723 | 2.49e-11 | 8.35e-10 | 173 |
| GO:000704416 | Oral cavity | OSCC | cell-substrate junction assembly | 67/7305 | 95/18723 | 4.51e-10 | 1.19e-08 | 67 |
| GO:015011517 | Oral cavity | OSCC | cell-substrate junction organization | 70/7305 | 101/18723 | 6.36e-10 | 1.63e-08 | 70 |
| GO:19019875 | Oral cavity | OSCC | regulation of cell cycle phase transition | 209/7305 | 390/18723 | 2.79e-09 | 6.42e-08 | 209 |
| GO:00457864 | Oral cavity | OSCC | negative regulation of cell cycle | 206/7305 | 385/18723 | 4.28e-09 | 9.55e-08 | 206 |
| GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
| GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
| GO:003158917 | Oral cavity | OSCC | cell-substrate adhesion | 193/7305 | 363/18723 | 2.48e-08 | 4.82e-07 | 193 |
| GO:00000753 | Oral cavity | OSCC | cell cycle checkpoint | 101/7305 | 169/18723 | 3.53e-08 | 6.68e-07 | 101 |
| GO:00070933 | Oral cavity | OSCC | mitotic cell cycle checkpoint | 81/7305 | 129/18723 | 3.75e-08 | 7.06e-07 | 81 |
| GO:004804110 | Oral cavity | OSCC | focal adhesion assembly | 59/7305 | 87/18723 | 4.86e-08 | 8.95e-07 | 59 |
| GO:00427707 | Oral cavity | OSCC | signal transduction in response to DNA damage | 102/7305 | 172/18723 | 5.27e-08 | 9.68e-07 | 102 |
| GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
| GO:00459304 | Oral cavity | OSCC | negative regulation of mitotic cell cycle | 132/7305 | 235/18723 | 6.51e-08 | 1.16e-06 | 132 |
| GO:003295620 | Oral cavity | OSCC | regulation of actin cytoskeleton organization | 189/7305 | 358/18723 | 6.81e-08 | 1.21e-06 | 189 |
| GO:00000863 | Oral cavity | OSCC | G2/M transition of mitotic cell cycle | 84/7305 | 137/18723 | 9.99e-08 | 1.70e-06 | 84 |
| GO:00448393 | Oral cavity | OSCC | cell cycle G2/M phase transition | 89/7305 | 148/18723 | 1.51e-07 | 2.51e-06 | 89 |
| GO:19019914 | Oral cavity | OSCC | negative regulation of mitotic cell cycle phase transition | 104/7305 | 179/18723 | 1.67e-07 | 2.73e-06 | 104 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TAOK2 | SNV | Missense_Mutation | c.340N>T | p.Asp114Tyr | p.D114Y | Q9UL54 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TAOK2 | SNV | Missense_Mutation | novel | c.3578N>T | p.Arg1193Leu | p.R1193L | Q9UL54 | protein_coding | deleterious_low_confidence(0) | benign(0.257) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| TAOK2 | SNV | Missense_Mutation | rs772517477 | c.1907N>A | p.Arg636His | p.R636H | Q9UL54 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TAOK2 | SNV | Missense_Mutation | c.671C>T | p.Pro224Leu | p.P224L | Q9UL54 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TAOK2 | SNV | Missense_Mutation | c.943N>T | p.Ile315Phe | p.I315F | Q9UL54 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TAOK2 | SNV | Missense_Mutation | rs770953476 | c.901G>A | p.Val301Met | p.V301M | Q9UL54 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| TAOK2 | insertion | Frame_Shift_Ins | novel | c.1492_1493insCTCACTGTTTCAAATTAGTATGGAT | p.Met498ThrfsTer27 | p.M498Tfs*27 | Q9UL54 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| TAOK2 | deletion | Frame_Shift_Del | novel | c.1686delG | p.Lys563SerfsTer32 | p.K563Sfs*32 | Q9UL54 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| TAOK2 | deletion | Frame_Shift_Del | novel | c.2593delG | p.Glu865ArgfsTer31 | p.E865Rfs*31 | Q9UL54 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| TAOK2 | SNV | Missense_Mutation | c.1465C>T | p.Arg489Trp | p.R489W | Q9UL54 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |